An interventional study of Lactase enzyme and Distilled water in Feeding Intolerance in Preterm Infants, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate whether adding lactase enzyme to milk feeds can improve feeding tolerance in preterm neonates. Preterm infants may have immature gastrointestinal function and reduced intestinal lactase activity, which may contribute to difficulty digesting lactose and symptoms of feeding intolerance. In this study, eligible preterm neonates will be randomly assigned to receive either lactase-treated milk feeds or placebo-treated milk feeds. Feeding tolerance will be assessed using clinical and nutritional parameters during the study period. The study will compare the two groups to determine whether lactase supplementation improves feeding tolerance and supports better progression of enteral feeding in preterm neonates. The hypothesis is that lactase-treated feeds will reduce feeding intolerance and facilitate achievement of adequate enteral feeding compared with placebo.
This is a randomized, controlled, parallel-group interventional study designed to evaluate the effect of lactase-treated feeds on feeding intolerance in preterm neonates.
Preterm neonates are at increased risk of feeding intolerance because of gastrointestinal immaturity, delayed gastric emptying, immature intestinal motility, and incomplete development of digestive enzyme activity. Lactase activity may be relatively low in preterm infants, potentially resulting in incomplete lactose digestion and contributing to gastrointestinal symptoms associated with feeding intolerance.
Eligible preterm neonates will be enrolled according to predefined inclusion and exclusion criteria. Participants will be randomly allocated into two groups. The intervention group will receive milk feeds treated with lactase enzyme, while the control group will receive milk feeds treated with placebo. The placebo will consist of distilled water administered in an equivalent manner to the lactase preparation.
The study will evaluate feeding tolerance throughout the study period. Clinical parameters related to feeding tolerance will be recorded, including the occurrence and severity of feeding intolerance manifestations and the progression of enteral feeding. Nutritional and growth-related parameters will also be assessed according to the study protocol.
The primary objective is to determine whether lactase-treated feeds improve feeding tolerance in preterm neonates compared with placebo-treated feeds. Secondary objectives include evaluating the effect of lactase supplementation on the progression of enteral feeding and selected nutritional and growth outcomes.
The study is expected to provide evidence regarding whether exogenous lactase supplementation may be beneficial in preterm neonates experiencing feeding intolerance
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Preterm neonates randomly assigned to this group will receive enteral feeds treated with lactase enzyme
Drug: Lactase enzyme
Preterm neonates randomly assigned to the control group will receive enteral feeds treated with an equivalent volume of sterile distilled water as placebo.
Other: Distilled water
Lactase enzyme treated feeds
Distilled water administered as placebo to the control group during enteral feeding.
Mean change from baseline in gastric residual volume
Gastric residual volume measured in milliliters before feeding and serially during the intervention period. The outcome will be assessed by comparing the change in gastric residual volume from baseline between the lactase-treated feed group and the placebo group.
Time frame: From start of intervention till 2 weeks
Number of participants with abdominal distension
Abdominal distension assessed clinically by serial abdominal examination and abdominal circumference measurement during the intervention period. Participants with clinically evident abdominal distension will be recorded.
Time frame: From initiation of intervention to 2weeks
Number of participants with vomiting
Vomiting episodes will be assessed by clinical observation during the intervention period and recorded for each participant.
Time frame: From initiation of intervention to 2 weeks
Number of participants with diarrhea
Diarrhea will be assessed clinically according to stool frequency and consistency during the intervention period and recorded for each participant.
Time frame: From initiation of intervention to 2 weeks
Mean change from baseline in body length
Body length measured in centimeters using a standardized infant length board. Length will be assessed at baseline and at the end of the intervention period.
Time frame: From initiation of the study intervention till 2 weeks
Mean change from baseline in body weight
Body weight measured in grams using a calibrated neonatal weighing scale. Weight will be measured serially during the study period and the change from baseline will be compared between the lactase-treated feed group and the placebo group.
Time frame: From initiation of intervention to 2 weeks
Mean change from baseline in head circumference
Head circumference measured in centimeters using a non-stretchable measuring tape placed around the largest occipital-frontal circumference. Measurements will be obtained at baseline and at the end of the intervention period.
Time frame: From initiation of intervention to 2 weeks
Mean change from baseline in mid-upper arm circumference
Mid-upper arm circumference measured in centimeters using a non-stretchable measuring tape at the midpoint of the upper arm. Measurements will be obtained at baseline and at the end of the intervention period.
Time frame: From initiation of intervention to 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Nov 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactase